Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin αvβ3-Targeted Radiotracer 99mTc-3P-RGD2

Zhou, Yang; Shao, Guoqiang; Liu, Shuang

doi:10.7150/thno.4443

Cited by 35 publications

(44 citation statements)

References 35 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In support of this hypothesis, i.v. injection of MDA-MB-231 cells is commonly used as a model for lung metastasis in which tumours grow following entrapment in the capillaries of the lung (Zhou et al 2012). In addition, MDA-MB-231 cells lack crucial molecules that are required for true homing, such as CXCR4 (reviewed Parker & Sukumar (2003)).…”

Section: Introductionmentioning

confidence: 99%

Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line

Nutter¹,

Holen²,

Brown³

et al. 2014

Endocrine-Related Cancer

106

View full text Add to dashboard Cite

Advanced breast cancer is associated with the development of incurable bone metastasis. The two key processes involved, tumour cell homing to and subsequent colonisation of bone, remain to be clearly defined. Genetic studies have indicated that different genes facilitate homing and colonisation of secondary sites. To identify specific changes in gene and protein expression associated with bone-homing or colonisation, we have developed a novel bone-seeking clone of MDA-MB-231 breast cancer cells that exclusively forms tumours in long bones following i.v. injection in nude mice. Bone-homing cells were indistinguishable from parental cells in terms of growth rate in vitro and when grown subcutaneously in vivo. Only bone-homing ability differed between the lines; once established in bone, tumours from both lines displayed similar rates of progression and caused the same extent of lytic bone disease. By comparing the molecular profile of a panel of metastasis-associated genes, we have identified differential expression profiles associated with bone-homing or colonisation. Bone-homing cells had decreased expression of the cell adhesion molecule fibronectin and the migration and calcium signal binding protein S100A4, in addition to increased expression of interleukin 1B. Bone colonisation was associated with increased fibronectin and upregulation of molecules influencing signal transduction pathways and breakdown of extracellular matrix, including hRAS and matrix metalloproteinase 9. Our data support the hypothesis that during early stages of breast cancer bone metastasis, a specific set of genes are altered to facilitate bone-homing, and that disruption of these may be required for effective therapeutic targeting of this process.

show abstract

Section: Introductionmentioning

confidence: 99%

Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line

Nutter¹,

Holen²,

Brown³

et al. 2014

Endocrine-Related Cancer

106

View full text Add to dashboard Cite

show abstract

“…Tc-3P-RGD 2 tumor uptake measured by percent injected dose (%ID)/cm 3 and tumor-to-muscle (T/M) ratio had a linear correlation with tumor b 3 and CD31, a marker for tumor blood vessels (Zhou et al, , 2012a. Tc-3P-RGD 2 SPECT/computed tomography (CT) was also used for quantification of tumor radioactivity accumulation and delineation of tumor necrotic regions (Zhou et al, 2012b;Shao et al, 2013). It is currently under clinical investigation as a new SPECT radiotracer for imaging carcinomas of breast and lung in cancer patients Zhu et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Monitoring Tumor Response to Linifanib Therapy with SPECT/CT Using the Integrinα_vβ₃–Targeted Radiotracer^99mTc-3P-RGD₂

Zhou

Voorbach

et al. 2013

J Pharmacol Exp Ther

Self Cite

View full text Add to dashboard Cite

The objective of this study was to determine the utility of Tc-3P-RGD 2 SPECT/CT imaging was performed at baseline (-1 day) and days 1, 4, 11, and 18. Tumors were harvested at all imaging time points for histopathological analysis with H&E and immunohistochemistry. A significant difference in tumor volumes between vehicle-and linifanib-treated groups was observed after 4 days of linifanib therapy in the U87MG model. The percent injected dose (%ID) tumor uptake of 99m Tc-3P-RGD 2 peaked in the vehicle-treated group at day 11, while the %ID/cm 3 tumor uptake decreased slowly over the whole study period. During the first 2 days of linifanib treatment, a rapid decrease in both % ID/cm 3 tumor uptake and tumor/muscle ratios of 99m Tc-3P-RGD 2 was observed, followed by a slow decrease until day 18. No decrease in tumor uptake of 99m Tc-3P-RGD 2 or tumor volume was observed for either treatment group in the PC-3 model. Changes in tumor vasculature were confirmed by histopathological H&E analysis and immunohistochemistry. Longitudinal imaging using 99m Tc-3P-RGD 2 SPECT/CT may be a useful tool for monitoring the downstream biologic effects of linifanib therapy.

show abstract

“…*Statistically significant difference (P < 0.05) between blocked and unblocked animals. However, the 99m Tc-TPPTS/HYNIC-PEG 4 -E-[PEG 4 -c(RGDfK)] 2 (PEG 4 = 15-amino-4,7,10,13-tetraoxapentadecanoic acid) radiopharmaceutical has shown mainly renal excretion in animal models and in patients with lung carcinoma [33,34]; therefore, a comparative study with 99m Tc-EDDA/HYNIC-E-[c(RGDfK)] 2 related to the in-vivo uptake in breast cancer tumours is necessary.…”

Section: Discussionmentioning

confidence: 99%

Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging

Ortiz-Arzate

Santos-Cuevas

Ocampo‐García

et al. 2014

Nuclear Medicine Communications

View full text Add to dashboard Cite

All absorbed doses were comparable to those known from most of the (99m)Tc studies. (99m)Tc-EDDA/HYNIC-E-[c(RGDfK)]2 obtained from kit formulations showed high tumour uptake in patients with malignant lesions, making it a promising imaging radiopharmaceutical for targeting site-specific breast cancer. The results obtained in this study warrant further clinical studies to determine the specificity and sensitivity of (99m)Tc-EDDA/HYNIC-E-[c(RGDfK)]2.

show abstract

Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin α_vβ₃-Targeted Radiotracer^99mTc-3P-RGD₂

Cited by 35 publications

References 35 publications

Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line

Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line

Monitoring Tumor Response to Linifanib Therapy with SPECT/CT Using the Integrinα_vβ₃–Targeted Radiotracer^99mTc-3P-RGD₂

Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging

Contact Info

Product

Resources

About

Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin αvβ3-Targeted Radiotracer 99mTc-3P-RGD2

Cited by 35 publications

References 35 publications

Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line

Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line

Monitoring Tumor Response to Linifanib Therapy with SPECT/CT Using the Integrinαvβ3–Targeted Radiotracer99mTc-3P-RGD2

Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging

Contact Info

Product

Resources

About

Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin α_vβ₃-Targeted Radiotracer^99mTc-3P-RGD₂

Monitoring Tumor Response to Linifanib Therapy with SPECT/CT Using the Integrinα_vβ₃–Targeted Radiotracer^99mTc-3P-RGD₂